Skip to Content
COVID-19 Resources
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 08/26/21

Cervical SPOREs

Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the “pap” smear test, 14,480 new cases and 4,290 deaths are projected in 2021. The 5-Year relative survival rate is 66.3% (2011-2017). The Johns Hopkins University Cervical SPORE was first funded in 2013, and its major activities are focused on the development of the next generation of novel preventive and therapeutic vaccines to improve treatment outcomes of patients with HPV-associated cervical cancer and its precursor lesions.